IMCD N.V.
ROTTERDAM, The Netherlands (9 March 2021) – IMCD N.V. ("IMCD" or "Company"), a leading distributor of speciality chemicals and ingredients, today announces that it has reached an agreement to sell its Nutri Granulations manufacturing asset and associated business to Huber Engineered Materials ("HEM"), a division of J.M. Huber Corporation ("Huber").
"Huber is an important supplier partner for IMCD and we are delighted to reach an agreement on the sale of Nutri Granulations," says Marcus Jordan, Americas President, IMCD. "HEM is a favorable long-term fit for Nutri Granulations and this agreement aligns with IMCD’s strategy to focus on the sales, marketing, and distribution of speciality chemicals and ingredients."
Located in La Mirada, CA, with 22 employees, Nutri Granulations manufactures food grade and USP grade calcium carbonate granulations for the nutraceuticals, food, over-the-counter, and pharmaceuticals markets. It was acquired by IMCD as part of the HORN acquisition in 2018.
"We are thrilled to add Nutri Granulations to our portfolio because their reputation for quality, reliability, and customer focus aligns perfectly with ours", adds Matt O'Brien, Senior Vice President and General Manager for HEM’s Ground Calcium Carbonate strategic business unit. "Also, adding an additional manufacturing site will support supply security and business continuity for our customers."
The closing of the transaction is planned for the end of March 2021.
Attached, please find the press release in pdf format.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
